v3.26.1
Subsequent Events (Details) - USD ($)
3 Months Ended 12 Months Ended
Aug. 27, 2026
Jul. 31, 2026
Sep. 30, 2026
Jun. 30, 2026
Jun. 30, 2025
Subsequent Events          
Proceeds from warrant exercises       $ 33,400,000  
Number of options granted       1,707,025 679,800
Exercise price       $ 1.87 $ 3.2
2025 Pre-Funded Warrants          
Subsequent Events          
Warrants exercised for common stock       9,250,394  
Proceeds from warrant exercises       $ 9,250  
Subsequent Events | AstralBio Amylin License Agreement          
Subsequent Events          
Payment of upfront licensing fee $ 750,000        
Aggregate potential milestone payments payable in licensing agreement $ 28,000,000        
Equity ownership (ceiling) 19.90%        
Subsequent Events | Stock Option Issuances - 2023 Plan | Employee Stock Option          
Subsequent Events          
Number of options granted     7,200    
Exercise price     $ 1.75    
Term of awards     P10Y    
Subsequent Events | Stock Option Issuances - 2023 Plan | Employee Stock Option | Vesting after one year          
Subsequent Events          
Stock options vesting percentage     25.00%    
Vesting period     1 year    
Subsequent Events | Stock Option Issuances - 2023 Plan | Employee Stock Option | Equal quarterly installments          
Subsequent Events          
Vesting period     36 months    
Subsequent Events | Stock Option Issuance - Employment Inducement Grant | Employee Stock Option          
Subsequent Events          
Number of options granted   430,000      
Exercise price   $ 1.4      
Term of awards   P10Y      
Subsequent Events | Stock Option Issuance - Employment Inducement Grant | Employee Stock Option | Vesting after one year          
Subsequent Events          
Stock options vesting percentage   25.00%      
Subsequent Events | Stock Option Issuance - Employment Inducement Grant | Employee Stock Option | Equal quarterly installments          
Subsequent Events          
Vesting period   36 months      
Subsequent Events | 2025 Pre-Funded Warrants          
Subsequent Events          
Warrants exercised for common stock     8,543,695    
Proceeds from warrant exercises     $ 8,544    
Subsequent Events | Series H Warrants          
Subsequent Events          
Warrants exercised for common stock     65,000    
Common stock issued upon exercise of warrants     65,000    
Proceeds from warrant exercises     $ 46,000